Recent News

• 05.19.2025 - 2025 Annual Meeting of Shareholders
• 05.19.2025 - 2025 Annual Meeting of Shareholders
• 04.25.2025 - Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
• 04.25.2025 - Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
• 04.17.2025 - Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions
• 04.17.2025 - Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions
• 04.11.2025 - Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.11.2025 - Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.08.2025 - Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
• 04.08.2025 - Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Recent Filings

• 04.23.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.08.2025 - EX-99.1 EX-99.1
• 04.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.08.2025 - 8-K Current report
• 03.28.2025 - ARS Annual Report to Security Holders
• 03.28.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.28.2025 - DEF 14A Other definitive proxy statements